Aduhelm
Aducanumab-avwa is a recombinant human immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta, and is expressed in a Chinese hamster ovary cell line. Aducanumab-avwa has an approximate molecular weight of 146 kDa.
ADUHELM (aducanumab-avwa) injection is a preservative-free, sterile, clear to opalescent, and colorless to yellow solution for intravenous infusion after dilution supplied in single-dose vials available in concentrations of 170 mg/1.7 mL (100 mg/mL) or 300 mg/3 mL (100 mg/mL) of ADUHELM.
Aduhelm Info
After an initial titration, the recommended dosage of ADUHELM is 10 mg/kg. ADUHELM is administered as an intravenous (IV) infusion over approximately one hour every four weeks and at least 21 days apart.
Intravenous
60
Minutes
Every
4
Weeks
Aduhelm Side Effects
The most common side effects include:
- amyloid related imaging abnormalities (ARIA) fluid retention (edema),
- headache,
- amyloid related imaging abnormalities due to haemosiderin deposition (ARIA-H) microhemorrhage,
- ARIA-H superficial siderosis,
- falls,
- diarrhea, and
- confusion/delirium/altered mental status/disorientation.
Patient Assistance Programs
There are several programs patients can sign up for that will assist in treatment costs:
Resources
To learn more about Aduhelm, browse the resources below.
Ready to get started?
Contact us to chat with one of our helpful scheduling specialists!